Insulin Delivery System Recalled by Roche
TUESDAY, March 29 (HealthDay News) --
ACCU-CHEK FlexLink Plus infusion sets are being recalled by their manufacturer, Roche, because the tube used for inserting the set may become kinked or bent, which could result in the under-delivery or no delivery of insulin, the U.S. Food and Drug Administration has announced.
Inadequate insulin can result in hyperglycemia, which can in turn result in serious complications such as diabetic ketoacidosis and death. Symptoms of hyperglycemia include nausea and vomiting, blurred vision, excessive thirst and/or hunger, fatigue, headache, abdominal pain, frequent urination, and fruity acetone breath. Anyone experiencing these symptoms should check their blood glucose level and consult their health care provider, according to Roche.
Roche has requested that customers refrain from using the ACCU-CHEK FlexLink Plus infusion sets and return unused products. The recall applies only to the ACCU-CHEK FlexLink Plus infusion sets that were launched in November 2010, and not to other infusion sets, such as ACCU-CHEK Ultraflex or other Accu-Chek infusion sets or insulin pumps.
According to the FDA, "patients are to contact their health care providers or caregivers to determine if changes to their therapy are needed and how to temporarily continue insulin pump therapy without the ACCU-CHEK FlexLink Plus infusion set."
More Information TUESDAY, March 29 (HealthDay News) -- ACCU-CHEK FlexLink Plus infusion sets are being recalled by their manufacturer, Roche, because the tube used for inserting the set may become kinked or bent, which could result in the under-delivery or no delivery of insulin, the U.S. Food and Drug Administration has announced.
Inadequate insulin can result in hyperglycemia, which can in turn result in serious complications such as diabetic ketoacidosis and death. Symptoms of hyperglycemia include nausea and vomiting, blurred vision, excessive thirst and/or hunger, fatigue, headache, abdominal pain, frequent urination, and fruity acetone breath. Anyone experiencing these symptoms should check their blood glucose level and consult their health care provider, according to Roche.
Roche has requested that customers refrain from using the ACCU-CHEK FlexLink Plus infusion sets and return unused products. The recall applies only to the ACCU-CHEK FlexLink Plus infusion sets that were launched in November 2010, and not to other infusion sets, such as ACCU-CHEK Ultraflex or other Accu-Chek infusion sets or insulin pumps.
According to the FDA, "patients are to contact their health care providers or caregivers to determine if changes to their therapy are needed and how to temporarily continue insulin pump therapy without the ACCU-CHEK FlexLink Plus infusion set."
More Information
Copyright © 2011 HealthDay. All rights reserved
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Tuesday, March 29, 2011
Insulin Delivery System Recalled by Roche
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment